Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma

Frontiers in Physiology

Volumn 5 MAR, Issue , 2014, Pages

  Reznik, Robert ^a   Hendifar, Andrew E ^a   Tuli, Richard ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Familiar pancreatic cancer; Pancreatic cancer oncogenes; Pancreatic cancer syndromes; Pancreatic cancer tumor suppressor genes; Pancreatic ductal adenocarcinoma

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; PROTEIN KINASE B BETA; PROTEIN P53; SMAD4 PROTEIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; SONIC HEDGEHOG PROTEIN; VASCULOTROPIN;

CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CAUSE OF DEATH; DNA REPAIR; EARLY DIAGNOSIS; FANCONI ANEMIA; FEMALE; GENE MUTATION; GENE PRODUCT; GENETIC PREDISPOSITION; HEREDITY; HIGH RISK POPULATION; HUMAN; MALE; PANCREAS ADENOCARCINOMA; REVIEW; RISK FACTOR; SCREENING TEST; SOLID TUMOR; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 84897939770     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00087     Document Type: Review

References (150)

1. Ardito, C. M., Gruner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., et al. (2012). EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22, 304-317. doi: 10.1016/j.ccr.2012.07.024.
2. Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., and Reddy, S. A. (2004). The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580. doi: 10.1038/sj.onc.1207902.
3. Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., and Reddy, S. A. (2005). The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem. Biophys. Res. Commun. 331, 295-302. doi: 10.1016/j.bbrc.2005.03.166.
4. Axilbund, J. E., Argani, P., Kamiyama, M., Palmisano, E., Raben, M., Borges, M., et al. (2009). Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol. Ther. 8, 131-135. doi: 10.4161/cbt.8.2.7136.
5. Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112. doi: 10.1038/nature08460.
6. Bartsch, D. K., Gress, T. M., and Langer, P. (2012). Familial pancreatic cancer-current knowledge. Nat. Rev. Gastroenterol. Hepatol. 9, 445-453. doi: 10.1038/nrgastro.2012.111.
7. Bartsch, D. K., Kress, R., Sina-Frey, M., Grutzmann, R., Gerdes, B., Pilarsky, C., et al. (2004). Prevalence of familial pancreatic cancer in Germany. Int. J. Cancer 110, 902-906. doi: 10.1002/ijc.20210.
8. Berger, N. A., Adams, J. W., Sikorski, G. W., Petzold, S. J., and Shearer, W. T. (1978). Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes. J. Clin. Invest. 62, 111-118. doi: 10.1172/JCI109094.
9. Bergmann, U., Funatomi, H., Yokoyama, M., Beger, H. G., and Korc, M. (1995). Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55, 2007-2011.
10. Berman, D. B., Costalas, J., Schultz, D. C., Grana, G., Daly, M., and Godwin, A. K. (1996). A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res. 56, 3409-3414.
11. Berman, D. M., Karhadkar, S. S., Maitra, A., Montes De Oca, R., Gerstenblith, M. R., Briggs, K., et al. (2003). Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425, 846-851. doi: 10.1038/nature01972.
12. Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., et al. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 15, 4674-4679. doi: 10.1158/1078-0432.CCR-09-0227.
13. Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., et al. (2012). A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest. New Drugs 30, 1216-1223. doi: 10.1007/s10637-011-9687-4.
14. Brand, R. E., Lerch, M. M., Rubinstein, W. S., Neoptolemos, J. P., Whitcomb, D. C., Hruban, R. H., et al. (2007). Participants of the fourth international symposium of inherited diseases of the, advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469. doi: 10.1136/gut.2006.108456.
15. Brand, R. E., and Lynch, H. T. (2006). Genotype/phenotype of familial pancreatic cancer. Endocrinol. Metabol. Clin. N. Am. 35, 405-415. doi: 10.1016/j.ecl.2006.02.015.
16. Breast Cancer Linkage Consortium. (1999). Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310-1316. doi: 10.1093/jnci/91.15.1310.
17. Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C., and Kimmey, M. B. (1999). Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131, 247-255. doi: 10.7326/0003-4819-131-4-199908170-00003.
18. Britten, C. D. (2013). PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother. Pharmacol. 71, 1395-1409. doi: 10.1007/s00280-013-2121-1.
19. Brune, K. A., Lau, B., Palmisano, E., Canto, M., Goggins, M. G., Hruban, R. H., et al. (2010). Importance of age of onset in pancreatic cancer kindreds. J. Natl. Cancer Inst. 102, 119-126. doi: 10.1093/jnci/djp466.
20. Brunner, T. B., Sauer, R., and Fietkau, R. (2011). Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiat. Oncol. 6:88. doi: 10.1186/1748-717X-6-88.
21. Bruns, C. J., Koehl, G. E., Guba, M., Yezhelyev, M., Steinbauer, M., Seeliger, H., et al. (2004). Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. 10, 2109-2119. doi: 10.1158/1078-0432.CCR-03-0502.
22. Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., et al. (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926-2935.
23. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917. doi: 10.1038/nature03443.
24. Bussom, S., and Saif, M. W. (2010). Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium." Orlando, FL. January 22-24, 2010. JOP 11, 128-130.
25. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., et al. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8, 27-32. doi: 10.1038/ng0994-27.
26. Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., et al. (2003). BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 163, 1255-1260. doi: 10.1016/S0002-9440(10)63485-2.
27. Canto, M. I., Goggins, M., Hruban, R. H., Petersen, G. M., Giardiello, F. M., Yeo, C., et al. (2006). Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 4, 766-781, quiz: 665. doi: 10.1016/j.cgh.2006.02.005.
28. Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., et al. (2013). International cancer of the pancreas screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339-347. doi: 10.1136/gutjnl-2012-303108.
29. Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., et al. (2009). BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349. doi: 10.1158/1535-7163.MCT-09-0499.
30. Cereda, S., Reni, M., Rognone, A., Fugazza, C., Ghidini, M., Ceraulo, D., et al. (2011). Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 57, 156-161. doi: 10.1159/000324865.
31. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., et al. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U.S.A. 93, 3636-3641. doi: 10.1073/pnas.93.8.3636.
32. Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K., de Andrade, M., Goggins, M., et al. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342-346. doi: 10.1158/1055-9965.EPI-06-0783.
33. Crane, C. H., Ellis, L. M., Abbruzzese, J. L., Amos, C., Xiong, H. Q., Ho, L., et al. (2006). Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. 24, 1145-1151. doi: 10.1200/JCO.2005.03.6780.
34. Crane, C. H., Varadhachary, G. R., Yordy, J. S., Staerkel, G. A., Javle, M. M., Safran, H., et al. (2011). Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J. Clin. Oncol. 29, 3037-3043. doi: 10.1200/JCO.2010.33.8038.
35. da Cunha Santos, G., Dhani, N., Tu, D., Chin, K., Ludkovski, O., Kamel-Reid, S., et al. (2010). Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: national cancer institute of Canada clinical trials group study PA.3. Cancer 116, 5599-5607. doi: 10.1002/cncr.25393.
36. Del Chiaro, M., Zerbi, A., Falconi, M., Bertacca, L., Polese, M., Sartori, N., et al. (2007). Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 7, 459-469. doi: 10.1159/000108963.
37. Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584. doi: 10.1038/nature02006.
38. di Magliano, M. P., and Logsdon, C. D. (2013). Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144, 1220-1229. doi: 10.1053/j.gastro.2013.01.071.
39. Ducreux, M., Boige, V., Goere, D., Deutsch, E., Ezra, P., Elias, D., et al. (2007). The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Best Pract. Res. Clin.Gastroenterol. 21, 997-1014. doi: 10.1016/j.bpg.2007.10.025.
40. Ehrenthal, D., Haeger, L., Griffin, T., and Compton, C. (1987). Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59, 1661-1664. doi: 10.1002/1097-0142(19870501)59:9<1661::AID-CNCR2820590923>3.0.CO;2-H.
41. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356. doi: 10.1038/nm.1890.
42. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921. doi: 10.1038/nature03445.
43. Feldmann, G., Karikari, C., dal Molin, M., Duringer, S., Volkmann, P., Bartsch, D. K., et al. (2011). Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol. Ther. 11, 959-968. doi: 10.4161/cbt.11.11.15534.
44. Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., et al. (2009). BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol. 27, 433-438. doi: 10.1200/JCO.2008.18.5546.
45. Friess, H., Berberat, P., Schilling, M., Kunz, J., Korc, M., and Buchler, M. W. (1996). Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med. 74, 35-42. doi: 10.1007/BF00202070.
46. Ghadirian, P., Boyle, P., Simard, A., Baillargeon, J., Maisonneuve, P., and Perret, C. (1991). Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol. 10, 183-196.
47. Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., et al. (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447-1453. doi: 10.1053/gast.2000.20228.
48. Goggins, M., Hruban, R. H., and Kern, S. E. (2000). BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am. J. Pathol. 156, 1767-1771. doi: 10.1016/S0002-9440(10)65047-X.
49. Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., et al. (1996). Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360-5364.
50. Gruis, N. A., van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., et al. (1995). Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat. Genet. 10, 351-353. doi: 10.1038/ng0795-351.
51. Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., et al. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 95, 214-221. doi: 10.1093/jnci/95.3.214.
52. Hahn, S. A., and Schmiegel, W. H. (1998). Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 59, 493-501. doi: 10.1159/000007526.
53. Hakam, A., Fang, Q., Karl, R., and Coppola, D. (2003). Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978. doi: 10.1023/A:1026122421369.
54. Hemminki, K., and Li, X. (2003). Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int. J. Cancer 103, 525-530. doi: 10.1002/ijc.10863.
55. Hewish, M., Chau, I., and Cunningham, D. (2009). Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 4, 54-72. doi: 10.2174/157489209787002515.
56. Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., and Depinho, R. A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249. doi: 10.1101/gad.1415606.
57. Hruban, R. H., Canto, M. I., Goggins, M., Schulick, R., and Klein, A. P. (2010). Update on familial pancreatic cancer. Adv. Surg. 44, 293-311. doi: 10.1016/j.yasu.2010.05.011.
58. Hruban, R. H., Goggins, M., Parsons, J., and Kern, S. E. (2000). Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972.
59. Hruban, R. H., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., Falatko, F., et al. (1999). Familial pancreatic cancer. Ann. Oncol. 10(Suppl. 4), 69-73. doi: 10.1093/annonc/10.suppl_4.S69.
60. Hruban, R. H., Petersen, G. M., Ha, P. K., and Kern, S. E. (1998). Genetics of pancreatic cancer. From genes to families. Surg. Oncol. Clin. N. Am. 7, 1-23.
61. Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., et al. (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 143, 545-554.
62. Hustinx, S. R., Hruban, R. H., Leoni, L. M., Iacobuzio-Donahue, C., Cameron, J. L., Yeo, C. J., et al. (2005). Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol. Ther. 4, 83-86. doi: 10.4161/cbt.4.1.1380.
63. Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., et al. (2009). DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813. doi: 10.1200/JCO.2008.17.7188.
64. Jacobs, E. J., Chanock, S. J., Fuchs, C. S., Lacroix, A., McWilliams, R. R., Steplowski, E., et al. (2010). Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int. J. Cancer 127, 1421-1428. doi: 10.1002/ijc.25148.
65. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., et al. (1993). Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937-1942. doi: 10.1126/science.8316834.
66. James, T. A., Sheldon, D. G., Rajput, A., Kuvshinoff, B. W., Javle, M. M., Nava, H. R., et al. (2004). Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 101, 2722-2726. doi: 10.1002/cncr.20700.
67. Jenne, D. E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., et al. (1998). Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18, 38-43. doi: 10.1038/ng0198-38.
68. Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., et al. (2009). Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217. doi: 10.1126/science.1171202.
69. Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806. doi: 10.1126/science.1164368.
70. Kelleher, F. C. (2011). Hedgehog signaling and therapeutics in pancreatic cancer. Carcinogenesis 32, 445-451. doi: 10.1093/carcin/bgq280.
71. Kindler, H. L., Friberg, G., Singh, D. A., Locker, G., Nattam, S., Kozloff, M., et al. (2005). Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040. doi: 10.1200/JCO.2005.01.9661.
72. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622. doi: 10.1200/JCO.2010.28.1386.
73. Kindler, H. L., Richards, D. A., Garbo, L. E., Garon, E. B., Stephenson, J. J. Jr., Rocha-Lima, C. M., et al. (2012). randomized, A, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann. Oncol. 23, 2834-2842. doi: 10.1093/annonc/mds142.
74. Klein, A. P. (2012). Genetic susceptibility to pancreatic cancer. Mol. Carcinog. 51, 14-24. doi: 10.1002/mc.20855.
75. Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J., et al. (2004). Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64, 2634-2638. doi: 10.1158/0008-5472.CAN-03-3823.
76. Klein, A. P., Hruban, R. H., Brune, K. A., Petersen, G. M., and Goggins, M. (2001). Familial pancreatic cancer. Cancer J. 7, 266-273.
77. Koorstra, J. B., Hustinx, S. R., Offerhaus, G. J., and Maitra, A. (2008). Pancreatic carcinogenesis. Pancreatology 8, 110-125. doi: 10.1159/000123838.
78. Kraakman-van der Zwet, M., Overkamp, W. J., van Lange, R. E., Essers, J., van Duijn-Goedhart, A., Wiggers, I., et al. (2002). Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22, 669-679. doi: 10.1128/MCB.22.2.669-679.2002.
79. Krainer, M., Silva-Arrieta, S., FitzGerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., et al. (1997). Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N. Engl. J. Med. 336, 1416-1421. doi: 10.1056/NEJM199705153362003.
80. Lal, G., Liu, G., Schmocker, B., Kaurah, P., Ozcelik, H., Narod, S. A., et al. (2000). Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 60, 409-416.
81. Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., and Ostrander, E. A. (1996). BRCA1 mutations in a population-based sample of young women with breast cancer. N. Engl. J. Med. 334, 137-142. doi: 10.1056/NEJM199601183340301.
82. Li, D., Xie, K., Wolff, R., and Abbruzzese, J. L. (2004a). Pancreatic cancer. Lancet 363, 1049-1057. doi: 10.1016/S0140-6736(04)15841-8.
83. Li, J., Kleeff, J., Giese, N., Buchler, M. W., Korc, M., and Friess, H. (2004b). Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int. J. Oncol. 25, 203-210.
84. Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281-5293. doi: 10.1200/JCO.2005.14.415.
85. LoRusso, P. M., Rudin, C. M., Reddy, J. C., Tibes, R., Weiss, G. J., Borad, M. J., et al. (2011). Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17, 2502-2511. doi: 10.1158/1078-0432.CCR-10-2745.
86. Lu, X., Xu, T., Qian, J., Wen, X., and Wu, D. (2002). Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin. Med. J. 115, 1632-1636.
87. Lubinski, J., Phelan, C. M., Ghadirian, P., Lynch, H. T., Garber, J., Weber, B., et al. (2004). Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam. Cancer 3, 1-10. doi: 10.1023/B:FAME.0000026816.32400.45.
88. Lynch, H. T., Fitzsimmons, M. L., Smyrk, T. C., Lanspa, S. J., Watson, P., McClellan, J., et al. (1990). Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am. J. Gastroenterol. 85, 54-60.
89. Lynch, H. T., Fusaro, R. M., Lynch, J. F., and Brand, R. (2008). Pancreatic cancer and the FAMMM syndrome. Fam. Cancer 7, 103-112. doi: 10.1007/s10689-007-9166-4.
90. Lynch, H. T., Smyrk, T., Kern, S. E., Hruban, R. H., Lightdale, C. J., Lemon, S. J., et al. (1996). Familial pancreatic cancer: a review. Semin. Oncol. 23, 251-275.
91. MacDermott, R. P., and Kramer, P. (1973). Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65, 137-139.
92. Maitra, A., Kern, S. E., and Hruban, R. H. (2006). Molecular pathogenesis of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 20, 211-226. doi: 10.1016/j.bpg.2005.10.002.
93. Maloney, E. K., McLaughlin, J. L., Dagdigian, N. E., Garrett, L. M., Connors, K. M., Zhou, X. M., et al. (2003). An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63, 5073-5083.
94. McFaul, C. D., Greenhalf, W., Earl, J., Howes, N., Neoptolemos, J. P., Kress, R., et al. (2006). Anticipation in familial pancreatic cancer. Gut 55, 252-258. doi: 10.1136/gut.2005.065045.
95. Mimeault, M., and Batra, S. K. (2010). Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol. Rev. 62, 497-524. doi: 10.1124/pr.109.002329.
96. Min, Y., Adachi, Y., Yamamoto, H., Ito, H., Itoh, F., Lee, C. T., et al. (2003). Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res. 63, 6432-6441.
97. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966. doi: 10.1200/JCO.2006.07.9525.
98. Moran, A., O'Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., et al. (2012). Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer 11, 235-242. doi: 10.1007/s10689-011-9506-2.
99. Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., et al. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62, 3789-3793.
100. Nair, P. N., De Armond, D. T., Adamo, M. L., Strodel, W. E., and Freeman, J. W. (2001). Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 20, 8203-8214. doi: 10.1038/sj.onc.1205044.
101. Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S., Brody, L. C., Kaback, M., et al. (1996). The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet. 14, 188-190. doi: 10.1038/ng1096-188.
102. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., et al. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461. doi: 10.1126/science.1171362.
103. Ouban, A., Muraca, P., Yeatman, T., and Coppola, D. (2003). Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol. 34, 803-808. doi: 10.1016/S0046-8177(03)00291-0.
104. Ozcelik, H., Schmocker, B., Di Nicola, N., Shi, X. H., Langer, B., Moore, M., et al. (1997). Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat. Genet. 16, 17-18. doi: 10.1038/ng0597-17.
105. Pasca di Magliano, M., Sekine, S., Ermilov, A., Ferris, J., Dlugosz, A. A., and Hebrok, M. (2006). Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev. 20, 3161-3173. doi: 10.1101/gad.1470806.
106. Patel, K. J., Yu, V. P., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., et al. (1998). Involvement of Brca2 in DNA repair. Mol. Cell 1, 347-357. doi: 10.1016/S1097-2765(00)80035-0.
107. Permuth-Wey, J., and Egan, K. M. (2009). Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam. Cancer 8, 109-117. doi: 10.1007/s10689-008-9214-8.
108. Phelan, C. M., Lancaster, J. M., Tonin, P., Gumbs, C., Cochran, C., Carter, R., et al. (1996). Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat. Genet. 13, 120-122. doi: 10.1038/ng0596-120.
109. Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., et al. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S(0205). J. Clin. Oncol. 28, 3605-3610. doi: 10.1200/JCO.2009.25.7550.
110. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165-167. doi: 10.1038/ng1959.
111. Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., et al. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54, 3025-3033.
112. Reichert, M., Saur, D., Hamacher, R., Schmid, R. M., and Schneider, G. (2007). Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 67, 4149-4156. doi: 10.1158/0008-5472.CAN-06-4484.
113. Reimer, R. R., Fraumeni, J. F. Jr., Ozols, R. F., and Bender, R. (1977). Pancreatic cancer in father and son. Lancet 1, 911. doi: 10.1016/S0140-6736(77)91244-2.
114. Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral inhibitor, MEK, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462. doi: 10.1200/JCO.2004.01.185.
115. Rowley, M., Ohashi, A., Mondal, G., Mills, L., Yang, L., Zhang, L., et al. (2011). Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140, 1303-1313.e1-e3. doi: 10.1053/j.gastro.2010.12.039.
116. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., et al. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731-1734.
117. Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., and Testa, J. R. (1998). Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81-86. doi: 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R.
118. Rulyak, S. J., Lowenfels, A. B., Maisonneuve, P., and Brentnall, T. A. (2003). Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 124, 1292-1299. doi: 10.1016/S0016-5085(03)00272-5.
119. Sato, N., Rosty, C., Jansen, M., Fukushima, N., Ueki, T., Yeo, C. J., et al. (2001). STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol. 159, 2017-2022. doi: 10.1016/S0002-9440(10)63053-2.
120. Schenk, M., Schwartz, A. G., O'Neal, E., Kinnard, M., Greenson, J. K., Fryzek, J. P., et al. (2001). Familial risk of pancreatic cancer. J. Natl. Cancer Inst. 93, 640-644. doi: 10.1093/jnci/93.8.640.
121. Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L., and Bold, R. J. (2003). Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 89, 2110-2115. doi: 10.1038/sj.bjc.6601396.
122. Schnall, S. F., and Macdonald, J. S. (1996). Chemotherapy of adenocarcinoma of the pancreas. Semin. Oncol. 23, 220-228.
123. Schneider, G., and Schmid, R. M. (2003). Genetic alterations in pancreatic carcinoma. Mol. Cancer 2:15. doi: 10.1186/1476-4598-2-15.
124. Schneider, R., Slater, E. P., Sina, M., Habbe, N., Fendrich, V., Matthai, E., et al. (2011). German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam. Cancer 10, 323-330. doi: 10.1007/s10689-010-9414-x.
125. Schonleben, F., Qiu, W., Ciau, N. T., Ho, D. J., Li, X., Allendorf, J. D., et al. (2006). PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin. Cancer Res. 12, 3851-3855. doi: 10.1158/1078-0432.CCR-06-0292.
126. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., et al. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810. doi: 10.1038/386804a0.
127. Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics (2013). CA Cancer J. Clin. 63, 11-30. doi: 10.3322/caac.21166.
128. Silverman, D. T., Schiffman, M., Everhart, J., Goldstein, A., Lillemoe, K. D., Swanson, G. M., et al. (1999). Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br. J. Cancer 80, 1830-1837. doi: 10.1038/sj.bjc.6690607.
129. Skoulidis, F., Cassidy, L. D., Pisupati, V., Jonasson, J. G., Bjarnason, H., Eyfjord, J. E., et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18, 499-509. doi: 10.1016/j.ccr.2010.10.015.
130. Slater, E. P., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., et al. (2010). PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 78, 490-494. doi: 10.1111/j.1399-0004.2010.01425.x.
131. Spano, J. P., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H., Barone, C., et al. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371, 2101-2108. doi: 10.1016/S0140-6736(08)60661-3.
132. Stoecklein, N. H., Luebke, A. M., Erbersdobler, A., Knoefel, W. T., Schraut, W., Verde, P. E., et al. (2004). Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J. Clin. Oncol. 22, 4737-4745. doi: 10.1200/JCO.2004.05.142.
133. Stoeltzing, O., Liu, W., Reinmuth, N., Fan, F., Parikh, A. A., Bucana, C. D., et al. (2003). Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 163, 1001-1011. doi: 10.1016/S0002-9440(10)63460-8.
134. Talar-Wojnarowska, R., and Malecka-Panas, E. (2006). Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med. Sci. Monit. 12, RA186-RA193.
135. Tanno, S., Tanno, S., Mitsuuchi, Y., Altomare, D. A., Xiao, G. H., and Testa, J. R. (2001). AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 61, 589-593.
136. Tersmette, A. C., Petersen, G. M., Offerhaus, G. J., Falatko, F. C., Brune, K. A., Goggins, M., et al. (2001). Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res. 7, 738-744.
137. Thompson, D., Easton, D. F., and Breast Cancer Linkage Consortium. (2002). Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94, 1358-1365. doi: 10.1093/jnci/94.18.1358.
138. Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., et al. (2009). Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137, 1183-1186. doi: 10.1053/j.gastro.2009.06.055.
139. van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F., et al. (2005). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42, 711-719. doi: 10.1136/jmg.2004.028829.
140. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., et al. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430-1438. doi: 10.1200/JCO.2004.10.112.
141. van der Heijden, M. S., Brody, J. R. Dezentje, D. A., Gallmeier, E., Cunningham, S. C., Swartz, M. J., et al. (2005). In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res. 11, 7508-7515. doi: 10.1158/1078-0432.CCR-05-1048.
142. Vasen, H. F., Wasser, M., van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., et al. (2011). Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140, 850-856. doi: 10.1053/j.gastro.2010.11.048.
143. Wang, W., Chen, S., Brune, K. A., Hruban, R. H., Parmigiani, G., and Klein, A. P. (2007). PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J. Clin. Oncol. 25, 1417-1422. doi: 10.1200/JCO.2006.09.2452.
144. Wilentz, R. E., Su, G. H., Dai, J. L., Sparks, A. B., Argani, P., Sohn, T. A., et al. (2000). Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am. J. Pathol. 156, 37-43. doi: 10.1016/S0002-9440(10)64703-7.
145. Willett, C. G., Kozin, S. V., Duda, D. G., di Tomaso, E., Kozak, K. R., Boucher, Y., et al. (2006). Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin. Oncol. 33, S35-S40. doi: 10.1053/j.seminoncol.2006.08.007.
146. Williamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A., Ye, R., Muzik, H., et al. (2012). Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol. Med. 4, 515-527. doi: 10.1002/emmm.201200229.
147. Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., et al. (2009). Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 27, 193-198. doi: 10.1200/JCO.2008.18.9514.
148. Xia, B., Sheng, Q., Nakanishi, K., Ohashi, A., Wu, J., Christ, N., et al. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729. doi: 10.1016/j.molcel.2006.05.022.
149. Xin, W., Yun, K. J., Ricci, F., Zahurak, M., Qiu, W., Su, G. H., et al. (2004). MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin. Cancer Res. 10, 8516-8520. doi: 10.1158/1078-0432.CCR-04-0885.
150. Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., et al. (2011). PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov. 1, 158-169. doi: 10.1158/2159-8290.CD-11-0031.